CKS1B

Across TCGA pan-cancer cohorts, CKS1B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CKS1B data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CKS1B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CKS1B expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where CKS1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	0.478	0.953	.005	14	view →
PDAC	DFS	Quartile	II,III,IV	0.132	0.529	.017	13	view →
LUAD	DFS	Quartile	III,IV	0.953	0.338	.006	3	view →
GBM	OS	Tertile	All	0.652	0.422	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CKS1B–CCRCC (OS)

Open the CCRCC breakdown →